Literature DB >> 23041125

A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes.

Ronald L Veselenak1, Mark Shlapobersky, Richard B Pyles, Qun Wei, Sean M Sullivan, Nigel Bourne.   

Abstract

Here we describe studies in the guinea pig model of genital herpes to evaluate a novel plasmid DNA (pDNA) vaccine encoding the HSV-2 glycoprotein D and UL46 and UL47 genes encoding tegument proteins VP11/12 and VP 13/14 (gD2/UL46/UL47), formulated with a cationic lipid-based adjuvant Vaxfectin(®). Prophylactic immunization with Vaxfectin(®)-gD2/UL46/UL47 significantly reduced viral replication in the genital tract, provided complete protection against both primary and recurrent genital skin disease following intravaginal HSV-2 challenge, and significantly reduced latent HSV-2 DNA in the dorsal root ganglia compared to controls. We also examined the impact of therapeutic immunization of HSV-2 infected animals. Here, Vaxfectin(®)-gD2/UL46/UL47 immunization significantly reduced both the frequency of recurrent disease and viral shedding into the genital tract compared to controls. This novel adjuvanted pDNA vaccine has demonstrated both prophylactic and therapeutic efficacy in the guinea pig model of genital herpes and warrants further development.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23041125      PMCID： PMC3807597          DOI： 10.1016/j.vaccine.2012.09.057

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  36 in total

1.  Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens.

Authors:  J Hartikka; V Bozoukova; M Ferrari; L Sukhu; J Enas; M Sawdey; M K Wloch; K Tonsky; J Norman; M Manthorpe; C J Wheeler
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

2.  Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization.

Authors:  L Reyes; J Hartikka; V Bozoukova; L Sukhu; W Nishioka; G Singh; M Ferrari; J Enas; C J Wheeler; M Manthorpe; M K Wloch
Journal:  Vaccine       Date:  2001-06-14       Impact factor: 3.641

3.  Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor.

Authors:  David M Koelle; Zhi Liu; Christopher L McClurkan; Randal C Cevallos; Jeffrey Vieira; Nancy A Hosken; Clement A Meseda; Devon C Snow; Anna Wald; Lawrence Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

4.  Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs.

Authors:  M G Myers; D I Bernstein; C J Harrison; L R Stanberry
Journal:  Antiviral Res       Date:  1988-11       Impact factor: 5.970

Review 5.  Herpes simplex virus infections.

Authors:  R J Whitley; B Roizman
Journal:  Lancet       Date:  2001-05-12       Impact factor: 79.321

6.  Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs.

Authors:  L R Stanberry; D I Bernstein; S Kit; M G Myers
Journal:  J Infect Dis       Date:  1986-06       Impact factor: 5.226

7.  Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.

Authors:  Nigel Bourne; Fernando J Bravo; Myriam Francotte; David I Bernstein; Martin G Myers; Moncef Slaoui; Lawrence R Stanberry
Journal:  J Infect Dis       Date:  2003-02-07       Impact factor: 5.226

Review 8.  Herpes simplex virus type 2 transmission: risk factors and virus shedding.

Authors:  Anna Wald
Journal:  Herpes       Date:  2004-08

9.  The potential epidemiological impact of a genital herpes vaccine for women.

Authors:  G P Garnett; G Dubin; M Slaoui; T Darcis
Journal:  Sex Transm Infect       Date:  2004-02       Impact factor: 3.519

10.  Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

Authors:  Lawrence Corey; Anna Wald; Raj Patel; Stephen L Sacks; Stephen K Tyring; Terri Warren; John M Douglas; Jorma Paavonen; R Ashley Morrow; Karl R Beutner; Leonid S Stratchounsky; Gregory Mertz; Oliver N Keene; Helen A Watson; Dereck Tait; Mauricio Vargas-Cortes
Journal:  N Engl J Med       Date:  2004-01-01       Impact factor: 91.245
View more
  29 in total

1.  Highly conserved intragenic HSV-2 sequences: Results from next-generation sequencing of HSV-2 UL and US regions from genital swabs collected from 3 continents.

Authors:  Christine Johnston; Amalia Magaret; Pavitra Roychoudhury; Alexander L Greninger; Anqi Cheng; Kurt Diem; Matthew P Fitzgibbon; Meei-Li Huang; Stacy Selke; Jairam R Lingappa; Connie Celum; Keith R Jerome; Anna Wald; David M Koelle
Journal:  Virology       Date:  2017-07-13       Impact factor: 3.616

2.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

Review 3.  Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.

Authors:  Joshua T Schiffer; Sami L Gottlieb
Journal:  Vaccine       Date:  2017-09-25       Impact factor: 3.641

4.  Current status and prospects for development of an HSV vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

5.  Development of disease and immunity at the genital epithelium following intrarectal inoculation of male guinea pigs with herpes simplex virus type 2.

Authors:  Nigel Bourne; Brianne N Banasik; Clarice L Perry; Aaron L Miller; Mellodee White; Richard B Pyles; Gregg N Milligan
Journal:  Virology       Date:  2018-11-06       Impact factor: 3.616

6.  Increased Frequency of Virus Shedding by Herpes Simplex Virus 2-Infected Guinea Pigs in the Absence of CD4+ T Lymphocytes.

Authors:  Nigel Bourne; Clarice L Perry; Brianne N Banasik; Aaron L Miller; Mellodee White; Richard B Pyles; Hubert Schäfer; Gregg N Milligan
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

7.  Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia.

Authors:  Viraj Kulkarni; Margherita Rosati; Antonio Valentin; Rashmi Jalah; Candido Alicea; Lei Yu; Yongjun Guan; Xiaoying Shen; Georgia D Tomaras; Celia LaBranche; David C Montefiori; Carmela Irene; Rajasekhar Prattipati; Abraham Pinter; Sean M Sullivan; George N Pavlakis; Barbara K Felber
Journal:  Hum Vaccin Immunother       Date:  2013-07-02       Impact factor: 3.452

8.  Detection of herpes simplex virus type 2 (HSV-2) -specific cell-mediated immune responses in guinea pigs during latent HSV-2 genital infection.

Authors:  Clarice L Perry; Brianne N Banasik; Summer R Gorder; Jingya Xia; Sarah Auclair; Nigel Bourne; Gregg N Milligan
Journal:  J Immunol Methods       Date:  2016-09-19       Impact factor: 2.303

9.  Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.

Authors:  Wen-Hsuan W Lin; Adrian Vilalta; Robert J Adams; Alain Rolland; Sean M Sullivan; Diane E Griffin
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

10.  Protection from genital herpes disease, seroconversion and latent infection in a non-lethal murine genital infection model by immunization with an HSV-2 replication-defective mutant virus.

Authors:  Fernando M Diaz; David M Knipe
Journal:  Virology       Date:  2015-11-21       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.